Use of the amplatz vascular plug II device to occlude different types of patent ductus arteriosus in pediatric patients

(1) Istanbul Mehmet Akif Ersoy, Thoracic and Cardiovascular Surgery Center and Research Hospital, Department of Pediatric Cardiology, Istanbul, Turkey
(2) Istanbul Mehmet Akif Ersoy, Thoracic and Cardiovascular Surgery Center and Research Hospital, Department of Pediatric Anesthesiology, Istanbul, Turkey

Objectives: To evaluate the outcome of the Amplatzer Vascular Plug II (AVP-II) for closure of the patent ductus arteriosus (PDA) in children.

Methods: All patients undergoing transcatheter closure of PDA with AVP II from June 2013 to November 2015 were retrospectively evaluated. Clinical, angiographic, and echocardiographic data were analyzed.

Results: Twenty procedures were performed in 19 patients. Median age was 18 months (6–202 months) with median weight 9.9 kg (5.1–63). The morphological PDA classification was Type A in 4/19 (21%), Type C in 14/19 (74%), and Type E in 1/21 (5%). The median minimum PDA diameter, maximum and length was 3.24 mm (1.7-4.7 mm), 8.47 mm (3.3-17 mm), and 12.79 mm (11-21 mm) respectively. The implanted device sizes were: 6 mm in 3/20 (15%), 8 mm in 9/20 (45%), and 10 mm in 8/20 procedures (45%). The implanted device was mean of 2.97±0.87 times the ductus narrowest diameter and mean of 1.03±0.36 times the ductus largest diameter in successful procedures. The mean procedure and fluoroscopy time was 35 minutes (15-60 minutes) and 8.4 minutes (3.1-12.8 minutes). In four patients closure was performed from the arterial side. All procedures except one were successful; among succesfull procedures 100% “in-lab” and 100% closure on post-procedural echocardiogram was achived. No left pulmonary artery stenosis and aortic obstruction observed with a median follow-up duration of 9 months (0-29 months).

Complications: In one patient device had to remove due to pulmonary hypertensive crisis. And in the last patient 8 mm device was embolized into the pulmonary artery due to ductal spasm which caused underestimation of the duct. And on the next day 8mm device was retrieved and a 10 mm device was implanted.

Conclusions: The AVP II seems to be an effective and safe device for PDA closure in children. It is particularly useful in type C and E ductus and in small infants where it eliminated the risk of device-related aortic obstruction.